Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus medication litifilimab. In return, Royalty Pharma will receive undisclosed ...

Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

Biogen has arrived at a highly unusual solution to a dispute surrounding a patent for its blockbuster multiple sclerosis drug Tecfidera. It has agreed to pay Denmark’s Forward Pharma $1.25 ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

In the arena of external deals, Biogen has secured an R&D investment in its lupus portfolio from Royalty Pharma plc (Nasdaq: RPRX). Biogen is set to receive R&D funding of up to $250 million from ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the ...

The only other time Biogen stock has spiked was in September 2022, when, alongside Japanese Pharma Eisai, its development partner in the Alzheimer's treatment field, the company shared data from a ...

Adjacencies and DTx The final focus area at Biogen Digital Health is digital therapeutics and other pharma-adjacent interventions. Hadjiat draws a distinction between patient-facing apps and DTx.

India's Sun Pharma to acquire Checkpoint Therapeutics ... 2025 EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug The European Union's medicines regulator on ...